Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Long-term safety of pegloticase in chronic gout refractory to conventional treatment

(2012) Michael A Becker et al.   ANNALS OF THE RHEUMATIC DISEASES

Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey

(2012) Puja P Khanna et al.   Health and Quality of Life Outcomes

Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide

(2011) N. Dalbeth et al.   ANNALS OF THE RHEUMATIC DISEASES

Reassessing serum urate targets in the management of refractory gout: can you go too low?

(2009) Michael S Hershfield   CURRENT OPINION IN RHEUMATOLOGY

Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout

(2009) M. A. BECKER et al.   JOURNAL OF RHEUMATOLOGY

Quality of Life and Disability in Patients with Treatment-Failure Gout

(2009) M. A. BECKER et al.   JOURNAL OF RHEUMATOLOGY

Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved

(2009) Ralf G. Thiele et al.   RHEUMATOLOGY INTERNATIONAL

Dual energy computed tomography in tophaceous gout

(2008) H K Choi et al.   ANNALS OF THE RHEUMATIC DISEASES

Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study

(2008) John S. Sundy et al.   ARTHRITIS AND RHEUMATISM

Resolution of gouty tophi after twelve weeks of pegloticase treatment

(2008) Herbert S. B. Baraf et al.   ARTHRITIS AND RHEUMATISM